Listing 3.04 Cystic Fibrosis in 2026: How FEV1 at or Below Table VII-A or VII-B, Three Hospitalizations, Chest-Tube Pneumothorax, Vascular Embolization Hemoptysis, or Two of Four Chronic Complications Meets the Rule
Cystic fibrosis is one of the few Blue Book listings with seven separate paths to approval. That is deliberate. SSA recognizes that CF affects the lungs, the gut, the pancreas, and the bones, and that a single measurement rarely captures the disease. Path A locks in on lung function. Path B counts hospitalizations. Path C flags collapsed lungs. Paths D through F track respiratory failure, hemorrhage, and low oxygen. Path G is the two-of-four combination that catches everyone else with meaningful chronic disease.
If you have CF, you almost certainly meet one of these paths at some point in your adult life. The question is documentation. This is the practical, verbatim breakdown for 2026, with the SSA tables and the record you need on file.
The Verbatim Text of Listing 3.04
Here are the seven paths as they read in the SSA Blue Book, section 3.04 of 20 CFR Part 404 Subpart P Appendix 1, in 2026.
3.04 Cystic fibrosis (documented as described in 3.00J2) with A, B, C, D, E, F, or G:
A. FEV1 (see 3.00E) less than or equal to the value in Table VII-A or VII-B for your age, sex, and height without shoes (see 3.00E3a).
B. Exacerbations or complications (see 3.00J3) requiring three hospitalizations of any length within a 12-month period and at least 30 days apart.
C. Spontaneous pneumothorax, secondary to CF, requiring chest tube placement.
D. Respiratory failure requiring invasive mechanical ventilation, noninvasive ventilation with BiPAP, or a combination of both treatments, for a continuous period of at least 48 hours, or for a continuous period of at least 72 hours if postoperatively.
E. Pulmonary hemorrhage requiring vascular embolization to control bleeding.
F. SpO2 measured by pulse oximetry either at rest, during a 6MWT, or after a 6MWT, less than or equal to the value in Table VIII, twice within a 12-month period and at least 30 days apart.
G. Two of the following exacerbations or complications within a 12-month period:
1. Pulmonary exacerbation requiring 10 consecutive days of intravenous antibiotic treatment.
2. Pulmonary hemorrhage (hemoptysis with more than blood-streaked sputum but not requiring vascular embolization) requiring hospitalization of any length.
3. Weight loss requiring daily supplemental enteral nutrition via a gastrostomy for at least 90 consecutive days or parenteral nutrition via a central venous catheter for at least 90 consecutive days.
4. CFRD requiring daily insulin therapy for at least 90 consecutive days.
Seven paths. One diagnosis anchor under section 3.00J2 (a documented CF diagnosis by sweat chloride test, CFTR genotyping, or nasal potential difference). Meet the anchor and any one path, and SSA is required to approve at Step 3.
Path A: The FEV1 Path
Path A is the classic lung function path. Your FEV1 has to fall at or below the value in Table VII-A (ages 18 to 19) or Table VII-B (age 20 or older) based on your height without shoes. Height in centimeters is the reference measurement. Weight and BMI do not enter the math.
Here is the verbatim Table VII from section 3.04A.
| Height without shoes | Table VII-A (age 18 to under 20) | Table VII-B (age 20 or older) | ||
|---|---|---|---|---|
| Female FEV1 at or below (L) | Male FEV1 at or below (L) | Female FEV1 at or below (L) | Male FEV1 at or below (L) | |
| Under 153 cm (under 60.25 in) | 1.65 | 1.90 | 1.45 | 1.60 |
| 153 to under 159 cm (60.25 to under 62.50 in) | 1.75 | 2.05 | 1.55 | 1.75 |
| 159 to under 164 cm (62.50 to under 64.50 in) | 1.85 | 2.15 | 1.65 | 1.90 |
| 164 to under 169 cm (64.50 to under 66.50 in) | 1.95 | 2.30 | 1.75 | 2.00 |
| 169 to under 174 cm (66.50 to under 68.50 in) | 2.05 | 2.45 | 1.85 | 2.15 |
| 174 to under 180 cm (68.50 to under 70.75 in) | 2.20 | 2.60 | 2.00 | 2.30 |
| 180 to under 185 cm (70.75 to under 72.75 in) | 2.35 | 2.75 | 2.10 | 2.45 |
| 185 cm or more (72.75 in or more) | 2.40 | 2.85 | 2.20 | 2.55 |
Spirometry has to follow section 3.00E rules. Post-bronchodilator values are the ones SSA uses, and the best of at least three acceptable efforts within the same testing session is what counts. The number needs to be BTPS-corrected (body temperature, ambient pressure, saturated with water vapor). Any reputable pulmonary function lab reports FEV1 this way by default.
The FEV1 has to satisfy the threshold at least once during the claim window. Unlike the 3.02 asthma path, 3.04A does not require two readings across time. One qualifying reading, well documented, is enough.
Path B: Three Hospitalizations in 12 Months
Path B counts admissions. Three hospitalizations of any length within a 12-month period and at least 30 days apart, for exacerbations or complications of CF. That is the entire rule.
Two watch-outs. First, the 30-day gap is measured from discharge to next admission. Two admissions less than 30 days apart count as one for this path. Second, all three admissions must be inpatient. Observation status is not inpatient. If your CF center placed you under observation for two of the three visits, the record does not meet the rule as written.
Section 3.00J3 defines the pulmonary exacerbation. Increased cough and sputum, hemoptysis, increased shortness of breath, fatigue, and reduced lung function are the flag signs. Treatment usually includes IV antibiotics and intensified airway clearance therapy such as chest percussion or increased nebulizer use. The admission does not need to be for pulmonary reasons only. A CF-related complication like distal intestinal obstruction syndrome, severe malnutrition, or CF-related diabetes decompensation also qualifies if the admission was driven by the CF diagnosis.
Path C: Spontaneous Pneumothorax With Chest Tube
Path C is a single-event path. A spontaneous pneumothorax secondary to CF, requiring chest tube placement, satisfies the rule. It does not need to recur. It does not need to last a specific duration. One documented event with a chest tube on the operative or bedside procedure note is enough.
Pneumothorax is common in advanced CF because of the cystic changes in the lung parenchyma. Blebs and bullae rupture, air enters the pleural space, and the lung collapses. Small pneumothoraces sometimes resolve with observation. Path C requires the intervention: an actual chest tube. Pigtail catheter placement counts under the same procedural umbrella if the report describes it as tube drainage of the pneumothorax.
Path D: Respiratory Failure Requiring Ventilation
Path D counts mechanical or noninvasive ventilation. The rule spells out three modes: invasive mechanical ventilation (intubated on a vent), noninvasive ventilation with BiPAP, or a combination. The continuous duration threshold is 48 hours or more (72 hours if postoperatively).
The reason for the ventilation matters. Post-op ventilation for a routine surgery does not satisfy the rule. The support has to be for respiratory failure, defined in section 3.00N as the inability to maintain adequate gas exchange. If your last CF admission required BiPAP for 72 hours to keep your CO2 down and your pH normal, that is Path D.
Path E: Hemorrhage Requiring Embolization
Path E is the massive hemoptysis path. Any pulmonary hemorrhage that required vascular embolization (usually bronchial artery embolization) to control bleeding meets the rule. One event is enough.
Bronchial artery embolization is the interventional radiology procedure where a catheter is threaded through the femoral or radial artery into the bronchial circulation and coils, glue, or particles are deployed to occlude the bleeding vessel. The IR report will name the procedure. That report is what your claim needs.
Path F: Chronic Low SpO2 by Altitude
Path F is the SpO2 path. Two SpO2 readings at or below the Table VIII threshold, taken at least 30 days apart within a 12-month period, at rest or during or after a six-minute walk test.
| Test site altitude | SpO2 at or below |
|---|---|
| Less than 3,000 feet above sea level | 89 percent |
| 3,000 to 6,000 feet | 87 percent |
| Over 6,000 feet | 85 percent |
Most of the United States sits at or below 3,000 feet, so the 89 percent threshold applies. Denver, Salt Lake City, Albuquerque, and Colorado Springs sit in the 3,000 to 6,000 range. Places like Aspen or Leadville are above 6,000. If your pulmonary function lab is in a high-altitude city, the threshold is more generous because the ambient PO2 is lower.
Path G: Two of Four Chronic Complications
Path G is the two-of-four catch-all for people with substantial disease but no single-event trigger.
- G1. Pulmonary exacerbation requiring 10 consecutive days of IV antibiotic treatment.
- G2. Pulmonary hemorrhage (hemoptysis with more than blood-streaked sputum but not requiring embolization) requiring hospitalization of any length.
- G3. Weight loss requiring daily supplemental enteral nutrition via gastrostomy for at least 90 consecutive days, or parenteral nutrition via central venous catheter for at least 90 consecutive days.
- G4. CFRD (CF-related diabetes) requiring daily insulin therapy for at least 90 consecutive days.
Two of the four, within a 12-month window. Section 3.00J4 spells out the timing rules. If both events are the acute ones (G1 and G2), they must be at least 30 days apart. If one is acute (G1 or G2) and one is chronic (G3 or G4), they can overlap. Two chronic complications (G3 plus G4) can also both be counted even if their 90-day windows overlap.
Documentation Playbook
- Diagnosis anchor. Sweat chloride test result at or above 60 mmol/L, or CFTR genotype identifying two disease-causing variants, or nasal potential difference testing. Get the actual report into your file.
- Spirometry. Pulmonary function test report showing post-bronchodilator FEV1 with height, sex, and age documented. BTPS-corrected.
- Hospital admissions. Discharge summaries for each of the three admissions in the 12-month window. Not observation records. Inpatient status noted.
- Procedure reports. Chest tube placement, bronchial artery embolization, mechanical or BiPAP ventilation duration.
- Pulse ox tracings. Cardiology or CF clinic notes with resting or 6MWT SpO2 readings. Two events at least 30 days apart.
- Chronic complication records. IV antibiotic course notes, hemoptysis admission summaries, feeding tube placement date and duration, insulin start date for CFRD.
Worked Case: Sofia, 28, Denver CO, Path A and Path G Combined
Sofia is 5 feet 4 inches (163 cm). Her post-bronchodilator FEV1 at her March 2026 CF center visit was 1.58 liters. She is female, age 20 or older, height in the 159 to under 164 range. Table VII-B threshold: 1.65 liters. Her 1.58 clears the threshold. Path A is satisfied on that single record.
She also had a 12-day IV antibiotic course for a Pseudomonas exacerbation in October 2025. Her CFRD was diagnosed in July 2025 and she has been on daily insulin since then. That is G1 plus G4, more than 30 days apart, both within a 12-month window. Path G is also satisfied.
Her attorney submitted both paths in the SSA-3441 disability report. DDS approved at Step 3 in 63 days. Because Sofia lives in Colorado, her Table VIII altitude threshold for any future Path F claim would be 87 percent (3,000 to 6,000 feet). See our See If You Qualify intake or Colorado state page.
Worked Case: Marcus, 34, Miami FL, Path B Three Hospitalizations
Marcus had three CF-related hospitalizations in 2025. January 15 to 21 for a pulmonary exacerbation with 8 days of IV antibiotics. May 3 to 8 for another exacerbation with 6 days of IV antibiotics. September 12 to 17 for a Burkholderia infection with 12 days of IV antibiotics.
All three were inpatient status. The gap between discharge January 21 and admission May 3 is 102 days. The gap between discharge May 8 and admission September 12 is 127 days. Both gaps are well over 30 days. All three admissions fell within a 12-month window (January 15, 2025 through January 14, 2026).
Path B is satisfied. His CF center's discharge summaries were submitted with the application. DDS approved at Step 3 in 78 days. Because none of the individual admissions met Path D duration for BiPAP, Path D was not asserted. Path B alone was enough. Read our Florida state page or use See If You Qualify.
What Happens if the FEV1 Is Above Threshold
If your FEV1 is above the Table VII value, do not stop. Check the other six paths. Many CF patients with preserved FEV1 in their 20s and 30s meet Path G with pulmonary exacerbations plus CFRD, or Path C with a single pneumothorax, or Path B with three admissions in a year.
If none of the seven paths meet, the claim moves to the RFC stage. Section 3.00J of the Blue Book instructs adjudicators to consider all effects of CF (respiratory limits, GI limits from pancreatic insufficiency and malabsorption, endocrine limits from CFRD, and psychological effects of chronic illness) when writing the RFC. A CF patient with FEV1 at 65 percent predicted but frequent exacerbations, chronic sinus infections, and CFRD can still land in a sedentary RFC with excess absenteeism, which is a Step 5 win.
Interaction With Other Listings
| CF complication | Additional listing to consider |
|---|---|
| CFRD requiring insulin | 9.00 Endocrine (rarely met, but supports RFC) |
| Severe malnutrition BMI under 17.5 | 5.08 Weight Loss Due to Digestive Disorder |
| Chronic Pseudomonas or Burkholderia colonization | Repeatedly satisfies 3.04B and 3.04G1 |
| CF liver disease with cirrhosis | 5.05 Chronic Liver Disease |
| Pulmonary hypertension secondary to CF | 3.09 Cor Pulmonale |
| Post-lung transplant year one | 3.11 Lung Transplant (auto-grant for 3 years) |
Not sure which of the seven paths fits your record?
Our intake form maps your CF medical events against every 3.04 path. It takes about 4 minutes.
See If You QualifyTiming, Back Pay, and Medicare
SSDI back pay runs from the established onset date, minus the 5-month waiting period. For someone approved in July 2026 with an onset date of March 1, 2025, that is 12 months of retroactive benefits (August 2025 through July 2026 payable). If Path B is your route and the three admissions took place across 2024 and 2025, your onset can often be pushed back to the first qualifying admission.
SSI back pay caps at the application filing date. The 2026 federal benefit rate is $1,003 for individuals and $1,505 for couples. Many CF patients qualify for both concurrent SSDI and SSI in the first year while their SSDI amount is still below the SSI FBR.
Medicare Part A eligibility begins 29 months after established onset date. CF care is expensive: CFTR modulators like Trikafta run over $300,000 per year at list price. Insurance bridging through Medicaid, ACA marketplace subsidies, or CF Foundation Compass counselors is important in the 29-month gap.
Frequently Asked Questions
Does taking Trikafta or another CFTR modulator disqualify me from 3.04?
No. The rule looks at your current lung function and clinical events. Trikafta improves FEV1 for many patients, but if your post-modulator FEV1 still hits Table VII values or you still have exacerbations meeting Paths B, C, D, E, F, or G, you meet the listing.
Do observation stays count for Path B?
No. Path B requires inpatient admission. Observation is not inpatient. Ask the medical records department at your CF center to confirm inpatient status on each of the three admissions before you file.
Can a nasal potential difference test replace the sweat chloride for diagnosis?
Yes. Section 3.00J2 accepts sweat chloride at or above 60 mmol/L, CFTR genotype with two disease-causing variants, or nasal potential difference testing.
Does Path A require post-bronchodilator FEV1?
Yes. Section 3.00E requires post-bronchodilator values for the spirometry to satisfy any 3.04A determination. The lab report will label the pre and post values.
What is the difference between Path D and Path E?
Path D is respiratory failure requiring 48 hours or more of ventilation. Path E is pulmonary hemorrhage requiring vascular embolization. Both are single-event paths. You can meet either or both.
Does CF-related diabetes count for Path G if I use an insulin pump?
Yes. Path G4 requires daily insulin therapy for at least 90 consecutive days. Pump-delivered insulin counts. Basal-bolus injections count. The delivery method does not matter.
How is height measured for Table VII?
Height without shoes. Centimeters is the reference measurement. The lab will record it on the pulmonary function report. If your medical record has different heights on different visits, the height at the time of the qualifying spirometry is the one that governs.
Next Steps
Pull your last year of CF center records. Look for: your most recent FEV1 value with height, sex, and age noted. All hospital admissions with dates and inpatient status. Any chest tube, embolization, or ventilator event. Two SpO2 readings at least 30 days apart. IV antibiotic courses of 10 days or more. Feeding tube placements. Insulin start dates.
Match each against the seven paths in this article. If any path is met on paper today, file. Do not wait for perfect records. The 12-month durational rule is satisfied by the medically expected duration of CF, so it does not slow the claim.
Use See If You Qualify to start. Our intake checks your record against every 3.04 path.